Focus Partners Wealth
CMPX icon

Focus Partners Wealth’s Compass Therapeutics CMPX Stock Holding History

Focus Partners Wealth’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$116K Buy
53,121
+38,829
+272% +$115K ﹤0.01% 2604
2026
Q1 		$75.6K Sell
14,292
-4,303
-23% -$24.8K ﹤0.01% 2544
2025
Q4 		$99.9K Buy
18,595
+2,790
+18% +$12.9K ﹤0.01% 2554
2025
Q3 		$56K Buy
15,805
+2,206
+16% +$6.97K ﹤0.01% 2157
2025
Q2 		$35.4K Sell
13,599
-2
-0% -$4 ﹤0.01% 1986
2025
Q1 		$25.8K Buy
13,601
+10
+0.1% +$27 ﹤0.01% 1864
2024
Q4 		$19.7K Buy
+13,591
New +$22.6K ﹤0.01% 1848

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Focus Partners Wealth's CMPX Position: Q2 2026 in Review

Focus Partners Wealth increased its Compass Therapeutics (CMPX) stake by 272% in Q2 2026, buying an estimated $115K and bringing the position to 53,121 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #2604.

Focus Partners Wealth first reported a position in CMPX in Q4 2024 and has held it in 7 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Focus Partners Wealth held 53,121 shares of Compass Therapeutics worth $116K as of Q2 2026.
  • Focus Partners Wealth bought 38,829 Compass Therapeutics shares in Q2 2026, an estimated $115K.
  • Compass Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2604 holding.
  • Focus Partners Wealth first reported a position in Compass Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.